Tokyo, Sept 29, 2009 (JCN Newswire) - KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Co., Ltd., and Eisai Co., Ltd. announced today the conclusion of a license agreement for Uritos(R) Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, discovered and developed by KYORIN. Under the terms of this agreement, KYORIN shall grant Eisai the exclusive rights to develop and market the agent in China, India, Sri Lanka and ASEAN countries ("licensed territory").
